Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients.

Derosa G, Ragonesi PD, Carbone A, Fogari E, D'Angelo A, Cicero AF, Maffioli P.

Pharmacol Res. 2013 Jul;73:20-6. doi: 10.1016/j.phrs.2013.04.005. Epub 2013 Apr 26.

PMID:
23624419
2.

Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.

Derosa G, Ragonesi PD, Carbone A, Fogari E, Bianchi L, Bonaventura A, Romano D, Cicero AF, Maffioli P.

Diabetes Technol Ther. 2012 Jun;14(6):475-84. doi: 10.1089/dia.2011.0278. Epub 2012 Apr 18.

PMID:
22512264
3.

Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study.

Derosa G, Ragonesi PD, Carbone A, Fogari E, D'Angelo A, Cicero AF, Maffioli P.

Expert Opin Pharmacother. 2012 Dec;13(18):2581-91. doi: 10.1517/14656566.2012.734499. Epub 2012 Nov 3.

PMID:
23121473
4.

Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.

Derosa G, Carbone A, Franzetti I, Querci F, Fogari E, Bianchi L, Bonaventura A, Romano D, Cicero AF, Maffioli P.

Diabetes Res Clin Pract. 2012 Oct;98(1):51-60. doi: 10.1016/j.diabres.2012.05.022. Epub 2012 Jun 9.

PMID:
22682949
5.

Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.

Derosa G, Bonaventura A, Bianchi L, Romano D, Fogari E, D'Angelo A, Maffioli P.

Metabolism. 2014 Jul;63(7):957-67. doi: 10.1016/j.metabol.2014.04.008. Epub 2014 Apr 23.

PMID:
24874591
6.

Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.

Derosa G, Cicero AF, Franzetti IG, Querci F, Carbone A, Ciccarelli L, D'Angelo A, Fogari E, Maffioli P.

Can J Physiol Pharmacol. 2013 Sep;91(9):724-32. doi: 10.1139/cjpp-2012-0300. Epub 2013 Apr 23.

PMID:
23984793
7.

A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function.

Derosa G, Carbone A, D'Angelo A, Querci F, Fogari E, Cicero AF, Maffioli P.

Expert Opin Pharmacother. 2012 Dec;13(17):2433-42. doi: 10.1517/14656566.2012.730519. Epub 2012 Oct 15.

PMID:
23061989
8.

Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.

Derosa G, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN, Fogari E, Maffioli P.

Pharmacotherapy. 2013 Aug;33(8):817-26. doi: 10.1002/phar.1301. Epub 2013 Jun 6.

PMID:
23744726
9.

Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin.

Derosa G, Carbone A, D'Angelo A, Querci F, Fogari E, Cicero AF, Maffioli P.

Intern Med. 2013;52(19):2179-87. Epub 2012 Mar 1.

10.

Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.

Derosa G, Maffioli P, Ferrari I, Mereu R, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Salvadeo SA.

Horm Metab Res. 2010 Aug;42(9):663-9. doi: 10.1055/s-0030-1255036. Epub 2010 Jun 17.

PMID:
20560108
11.

Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.

Derosa G, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN, Fogari E, Maffioli P.

Diabet Med. 2012 Dec;29(12):1515-23. doi: 10.1111/j.1464-5491.2012.03699.x.

PMID:
22540883
12.

Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus.

Kothny W, Foley J, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V.

Diabetes Obes Metab. 2013 Mar;15(3):252-7. doi: 10.1111/dom.12020. Epub 2012 Nov 1.

PMID:
23039321
13.

Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.

Guarino E, Nigi L, Patti A, Fondelli C, Dotta F.

Expert Opin Pharmacother. 2012 Jun;13(9):1377-84. doi: 10.1517/14656566.2012.667078. Epub 2012 Mar 7. Review.

PMID:
22397507
14.

Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.

Derosa G, Bonaventura A, Bianchi L, Romano D, Fogari E, D'Angelo A, Maffioli P.

Diabet Med. 2014 Dec;31(12):1515-23. doi: 10.1111/dme.12499. Epub 2014 Jun 19.

PMID:
24824633
15.

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.

Metabolism. 2010 Jun;59(6):887-95. doi: 10.1016/j.metabol.2009.10.007. Epub 2009 Dec 16.

PMID:
20015525
16.

Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.

Pan C, Xing X, Han P, Zheng S, Ma J, Liu J, Lv X, Lu J, Bader G; Institution Investigators.

Diabetes Obes Metab. 2012 Aug;14(8):737-44. doi: 10.1111/j.1463-1326.2012.01593.x. Epub 2012 Apr 1.

PMID:
22369287
17.

Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus.

Forst T, Dworak M, Berndt-Zipfel C, Löffler A, Klamp I, Mitry M, Pfützner A.

Diabetes Obes Metab. 2013 Jun;15(6):576-9. doi: 10.1111/dom.12063. Epub 2013 Feb 6.

PMID:
23384119
18.
19.

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.

Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S.

Diabetes Obes Metab. 2009 Feb;11(2):157-66. doi: 10.1111/j.1463-1326.2008.00994.x. Erratum in: Diabetes Obes Metab. 2009 Apr;11(4):405.

PMID:
19125777
20.

Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.

Goodman M, Thurston H, Penman J.

Horm Metab Res. 2009 May;41(5):368-73. doi: 10.1055/s-0028-1104604. Epub 2009 Feb 16.

PMID:
19221978
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk